Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

1(50.0%)

Phase 3

1(50.0%)

2Total

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01016613Recruiting

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

Role: collaborator

NCT02190513Completed

Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease

Role: lead

NCT02174497Completed

One-Day Versus Three-Day Bowel Preparation for Colonoscopy in Children

Role: lead

NCT01287832Phase 4Terminated

Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

Role: lead

NCT01788124Completed

A Prospective Trial Comparing Metal to Plastic Speculums for Patient Comfort

Role: lead

NCT01050595Phase 3Unknown

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

Role: lead

All 6 trials loaded